A new era in speech therapy.
Clinical-grade care, delivered at home.
Overview
Specialist-Led Digital Therapy
We deliver clinical-grade speech therapy directly to your home, tailored by our team of experienced clinicians.
Demonstrated Benefits to Speech
Our evidence-based digital program can help increase speech clarity by improving vocal control, voice quality, and sound precision.
Customised for Progressive Conditions
SpeechATTAX is specifically designed for individuals with progressive neurological conditions such as Freidreich’s ataxia.
SpeechATTAX is a product of Melbourne Digital Therapeutics (DTx), a growing platform for digital therapeutic tools. It delivers innovative solutions for the future of care.
Program
-
SpeechATTAX is an intensive, home-based therapy designed to improve clarity of speech. It is delivered exclusively through our secure digital application.
-
SpeechATTAX is specifically designed for individuals with progressive neurological conditions, such as Friedreich’s ataxia and SCA1.
-
Users complete daily speech exercises targeting loudness, pitch and clarity, as well as functional phrases for real life.
-
Biofeedback is what sets us apart. Users receive instant audio and visual feedback, allowing them to see their progress in real time.
-
Users practice for 45 to 60 minutes per day, with specific tasks allocated by our experienced clinicians.
-
Click the Sign Up button at the top of the page, or scroll down to leave us your information. We will be in contact shortly!
Evidence
SpeechATTAX is a product of the world’s largest randomised controlled trial in speech therapy for progressive ataxia, involving 160 participants across four countries: Australia, New Zealand, Germany, and France.
In this multinational clinical trial, participants completing the four-week SpeechATTAX intervention demonstrated statistically significant improvements in speech intelligibility (p = 0.0009) – the primary outcome measuring how well a speaker can be understood in spontaneous speech. Treatment effects were also observed across multiple secondary endpoints, including speech naturalness, vocal control, articulatory precision, and patient-reported communication outcomes.
Objective acoustic analysis further confirmed treatment effects, including reduced vocal instability and improved control of pitch and loudness. These findings indicate measurable improvements in underlying speech motor control.
The trial builds on earlier controlled research demonstrating that biofeedback-driven speech therapy significantly improves dysarthria in genetic ataxias. 75% of participants showed measurable improvements in intelligibility following treatment.
Together, these studies provide robust clinical evidence that structured, biofeedback-driven speech therapy can improve communication in progressive cerebellar conditions. Findings establish SpeechATTAX as one of the first evidence-based digital therapeutics for dysarthria in progressive conditions.
Testimonials
“My speech improved so much... that friends complimented me on the clarity of my diction.”
-
I’ve used the SpeechATAX programme once every 18 months, for approximately seven years and I’m happy to endorse it wholeheartedly!
My speech improved so much the first two times I did the programme, that friends complimented me on the clarity of my diction. I’ve used it in the intensive mode as prescribed, but also occasionally as a refresher, and my speech has never deteriorated to that level since.
I’m much more confident in my interactions with friends and strangers alike, in person and even over the phone.
I have Friedreich ataxia (FA) whose most obvious symptoms on first presentation, are poor balance, clumsiness and slurred speech. It’s a vanishingly rare condition (there are fewer than 400 FAers in all of Australia), it’s often a tortuous journey from symptom presentation to confirmed diagnosis, and the future can seem very bleak from there. FA is a progressive, degenerative condition and deterioration is inevitable.
By the time of a confirmed diagnosis though, many aspects of one’s condition can actually be improved. They’ve deteriorated further than they needed to, simply for lack of attention. Importantly also, with continued intervention, it’s possible to make a material difference to the rate of further deterioration.
SpeechATAX has a variety of exercises to challenge every aspect of how I speak. I pick up pointers and strategies that I use long after I’ve finished the intensive programme.
I’m aware that managing speech is only one of the many complicated functions that my tongue gets up to but I’ve found that as I’ve maintained quality in my speech I’ve avoided other tongue and swallowing issues too.
Our Story
Communication is at the heart of the human experience. It connects us with others, and shapes how we move through the world.
SpeechATTAX was created to support those facing progressive conditions – individuals who are often left without specialised, consistent therapy as their needs evolve. Our focus is simple: delivering intensive, evidence-based care directly into the home, and supporting proactivity and accessibility.
Because every voice deserves to be heard clearly.
Meet the Team
-
![Black and white portrait of a man with short hair, wearing a collared shirt, tie, and sweater, against a dark background.]()
Adam Vogel
INVENTOR
Adam Vogel PhD is the Inventor of SpeechATTAX and CEO of Melbourne Digital Therapeutics. He has an international track record for developing speech endpoints that guide decisions about brain function and quality of life.Adam holds a PhD in behavioural neuroscience from the University of Melbourne, and degrees in psychology and speech science from the University of Queensland. He is also Director of the Centre for Neuroscience of Speech at the University of Melbourne. Adam maintains strong research alliances with the leading clinical centres in Australia, Europe and the United States.
-
![Black and white close-up photo of a man with curly hair, a beard, smiling and looking to his left, wearing a black shirt against a solid dark background.]()
Lucas Raniolo
PRODUCT LEAD
Lucas Raniolo is the Product Lead at SpeechATTAX. He is a PhD candidate in Speech Neuroscience at the University of Melbourne, and holds tertiary degrees in speech pathology and psychology (MSp, BSc).Lucas collaborates with international research teams to investigate complex neurological conditions.
